Clover Health Investments, Corp. (CLOV) Key Metrics
CLOV valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.38B
- Enterprise value
- $2.10B
- P/E (TTM)
- —
- Forward P/E
- 37.7
- PEG ratio
- —
- Price / sales
- 1.0 10-yr median 0.9
- Price / book
- 6.5 10-yr median 3.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.46
CLOV key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCLOV valuation Price multiples at each fiscal year-end price.
Price / sales−43.9%
0.6
2025 · hover or tap a bar for each year
20182025
Price / book−13.0%
3.9
2025 · hover or tap a bar for each year
20182025
Free cash flow yield−7.8 pts
−5.7%
2025 · hover or tap a bar for each year
20182025
CLOV returns How much profit the business earns on the capital it uses.
Return on equity−12.6 pts
−26.3%
2025 · hover or tap a bar for each year
20182025
Return on invested capital+0.9 pts
−40.6%
2025 · hover or tap a bar for each year
20182025
Return on assets−7.8 pts
−15.3%
2025 · hover or tap a bar for each year
20182025
Free cash flow margin−6.0 pts
−3.6%
2025 · hover or tap a bar for each year
20182025
Asset turnover+44.1%
3.43
2025 · hover or tap a bar for each year
20182025
CLOV per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+33.0%
$3.72
2025 · hover or tap a bar for each year
20182025
Earnings per share
−$0.17
2025 · hover or tap a bar for each year
20182025
Free cash flow per share
−$0.13
2025 · hover or tap a bar for each year
20182025
Book value per share−14.3%
$0.60
2025 · hover or tap a bar for each year
20182025
Shares outstanding+5.6%
517.2M
2025 · hover or tap a bar for each year
20182025
CLOV financial health Debt, liquidity and how easily interest is covered.
Net debt+$126.2M
−$95.3M
2025 · hover or tap a bar for each year
20182025
Current ratio−8.3%
1.47
2025 · hover or tap a bar for each year
20182025
CLOV efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding0 days
24 days
2025 · hover or tap a bar for each year
20182025
Days payables outstanding−5 days
8 days
2025 · hover or tap a bar for each year
20182025
Cash conversion cycle+5 days
16 days
2025 · hover or tap a bar for each year
20182025
Capex / revenue0.0 pts
0.1%
2025 · hover or tap a bar for each year
20182025
CLOV valuation history
Fiscal year-endToday8-year median
CLOV returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CLOV debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CLOV cash returned to shareholders
DividendsBuybacksFree cash flow
CLOV price vs earnings per share
Share price at year-endEPS (right axis)
CLOV key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $1.22B | $1.54B | $459.1M | $442.7M | $1.75B | $6.78B | — | — |
| Enterprise value | $1.12B | $1.32B | $227.5M | $113.8M | $1.16B | $6.82B | — | — |
| Price / sales | 0.6 | 1.1 | 0.4 | 0.4 | 1.2 | 10.1 | — | — |
| Price / book | 3.9 | 4.5 | 1.6 | 1.2 | 3.3 | — | — | — |
| Price / free cash flow | — | 46.4 | — | — | — | — | — | — |
| Price / operating cash flow | — | 44.3 | — | — | — | — | — | — |
| EV / sales | 0.6 | 1.0 | 0.2 | 0.1 | 0.8 | 10.1 | — | — |
| EV / free cash flow | — | 39.7 | — | — | — | — | — | — |
| Earnings yield | −7.0% | −2.8% | −46.5% | −76.7% | −33.6% | −2.0% | — | — |
| Free cash flow yield | −5.7% | 2.2% | −25.4% | −47.1% | −16.2% | −1.8% | — | — |
| Dividend yield | — | — | — | — | 0.0% | 0.0% | — | — |
| Shareholder yield (dividends + buybacks) | 4.5% | 1.2% | 1.4% | 1.4% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $2.35 | $3.15 | $0.95 | $0.93 | $3.72 | $16.77 | — | — |
| Per share | ||||||||
| Revenue per share | $3.72 | $2.80 | $2.61 | $2.30 | $3.13 | $1.66 | $1.14 | — |
| Earnings per share | −$0.17 | −$0.09 | −$0.44 | −$0.71 | −$1.25 | −$0.34 | −$0.90 | — |
| Operating cash flow per share | −$0.13 | $0.07 | −$0.24 | −$0.43 | −$0.60 | −$0.29 | −$0.40 | — |
| Free cash flow per share | −$0.13 | $0.07 | −$0.24 | −$0.44 | −$0.60 | −$0.29 | −$0.40 | — |
| Cash per share | $0.18 | $0.45 | $0.49 | $0.70 | $1.31 | $0.24 | $0.17 | — |
| Book value per share | $0.60 | $0.70 | $0.59 | $0.75 | $1.14 | −$1.53 | −$0.00 | — |
| Tangible book value per share | $0.59 | $0.69 | $0.59 | $0.71 | $1.13 | −$1.54 | −$0.01 | — |
| Dividends per share | — | — | — | — | $0.00 | $0.00 | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.00 | — |
| Debt per share | — | — | $0.01 | $0.01 | $0.06 | $0.34 | $0.14 | — |
| Shares outstanding | 517.2M | 490.0M | 482.2M | 476.2M | 470.9M | 404.4M | 404.4M | — |
| Change in shares outstanding | +5.6% | +1.6% | +1.2% | +1.1% | +16.4% | 0.0% | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −26.3% | −13.7% | −66.3% | −76.1% | — | — | — | — |
| Return on invested capital (ROIC) | −40.6% | −41.4% | −391.7% | — | — | — | — | — |
| Return on assets (ROA) | −15.3% | −7.5% | −30.9% | −38.6% | −96.5% | −102.0% | −345.3% | −95.9% |
| Return on tangible assets | −15.9% | −7.4% | −37.6% | −43.1% | −62.2% | −52.1% | — | −97.3% |
| Free cash flow margin | −3.6% | 2.4% | −9.2% | −19.0% | −19.2% | −17.7% | −34.6% | −55.1% |
| Financial health | ||||||||
| Total debt | — | — | $4.7M | $5.9M | $27.8M | $138.4M | $57.9M | $49.3M |
| Cash & short-term investments | $95.3M | $221.5M | $236.2M | $334.8M | $615.3M | $96.7M | $67.6M | $75.4M |
| Net debt | −$95.3M | −$221.5M | −$231.6M | −$328.9M | −$587.4M | $41.6M | −$9.7M | −$26.2M |
| Debt / equity | — | — | 0.02 | 0.02 | 0.05 | — | — | — |
| Debt / assets | — | — | 0.01 | 0.01 | 0.03 | 0.52 | 577.17 | 0.23 |
| Current ratio | 1.47 | 1.61 | 1.64 | 1.45 | 2.02 | 1.16 | 572.98 | 12.51 |
| Quick ratio | 1.47 | 1.61 | 1.37 | 1.68 | 2.43 | 2.42 | 572.98 | 12.51 |
| Interest coverage | — | — | — | -210.3 | -37.7 | -1.6 | -4.7 | — |
| Working capital | $99.0M | $129.6M | $166.9M | $193.5M | $379.9M | $25.6M | $67.5M | $69.4M |
| Invested capital | $213.4M | $119.6M | $54.8M | $28.0M | −$52.0M | −$575.4M | −$9.7M | −$81.0M |
| Tangible asset value | $305.7M | $338.2M | $283.4M | $336.9M | $533.8M | −$618.7M | −$4.3M | −$57.8M |
| Net current asset value | $75.5M | $103.5M | $143.7M | $173.3M | $341.1M | −$690.7M | $67.5M | −$190.0M |
| Graham net-net per share | −$0.03 | $0.11 | $0.11 | −$0.09 | $0.44 | −$2.04 | $0.25 | — |
| Capital allocation | ||||||||
| Dividends paid | — | — | — | — | $305,000 | $957,000 | — | — |
| Share buybacks (net) | $55.2M | $18.3M | $6.2M | $6.4M | $147,000 | $957,000 | $0 | — |
| Dividends + buybacks / free cash flow | — | 54.9% | — | — | — | — | — | — |
| Capex / revenue | 0.1% | 0.1% | 0.0% | 0.4% | 0.0% | 0.1% | 0.0% | 0.5% |
| Capex / operating cash flow | — | 4.5% | — | — | — | — | — | — |
| Capex / depreciation | 1.21 | 1.17 | 0.23 | 3.76 | 0.58 | 1.25 | 0.04 | 3.03 |
| Stock-based compensation / revenue | 5.4% | 8.3% | 11.2% | 15.0% | 11.1% | 1.1% | 0.7% | 1.3% |
| SG&A / revenue | 9.2% | 29.8% | 34.9% | 44.0% | 30.3% | 28.5% | 40.5% | 66.6% |
| Efficiency | ||||||||
| Days sales outstanding | 23.9 | 23.8 | 36.7 | 46.1 | 24.1 | 35.1 | 34.0 | 54.2 |
| Days of inventory on hand | — | — | -5.8 | -47.0 | -42.6 | -128.7 | — | — |
| Days payables outstanding | 8.2 | 13.0 | 12.6 | 11.1 | 6.9 | 45.0 | 104.1 | — |
| Cash conversion cycle (days) | 15.6 | 10.8 | 18.3 | -12.0 | -25.4 | -138.6 | -70.1 | — |
| Receivables turnover | 15.30 | 15.32 | 9.93 | 7.92 | 15.15 | 10.39 | 10.72 | 6.74 |
| Payables turnover | 44.32 | 28.05 | 28.86 | 32.79 | 52.76 | 8.11 | 3.51 | 0.00 |
| Asset turnover | 3.43 | 2.38 | 1.83 | 1.25 | 2.42 | 5.03 | 4.39 | 1.33 |
| Average receivables | $125.8M | $89.5M | $126.9M | $138.5M | $97.2M | $64.7M | $43.1M | $41.7M |
| Average payables | $35.4M | $35.9M | $34.8M | $30.3M | $29.4M | $72.8M | $128.3M | $141.8M |
| Average inventory | — | — | −$15.9M | −$127.9M | −$181.0M | −$208.0M | — | — |
| Intangibles / total assets | 0.6% | 0.5% | 0.5% | 2.5% | 0.6% | 2.0% | 4,218.4% | 1.4% |
Computed from CLOV's annual financial statements (latest annual report filed February 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CLOV valuation and financial ratios
Clover Health Investments earned a return on equity of −26.3% and a return on invested capital of −40.6% in fiscal 2025. It returned $55.2 million to shareholders: $0 in dividends and $55.2 million in share buybacks.
See the CLOV income statement, the CLOV chart for price history, or the CLOV stock overview for the latest quote and news.
CLOV key metrics FAQ
What is Clover Health Investments's return on equity?
Clover Health Investments's return on equity (ROE) was −26.3% in fiscal 2025: net income of -$85.5 million on average shareholders' equity of $324.9 million.
What is Clover Health Investments's ROIC?
Clover Health Investments's return on invested capital was −40.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
Does Clover Health Investments buy back its shares?
Yes. Clover Health Investments spent $55.2 million on net share repurchases in fiscal 2025 Shares outstanding changed +5.6% over the year, to 517.2M..
What is Clover Health Investments's free cash flow yield?
Clover Health Investments generated -$69.0 million of free cash flow in fiscal 2025, a free cash flow yield of −5.7% on its market value at year-end ($1.2 billion).
What is Clover Health Investments's current ratio?
Clover Health Investments's current ratio was 1.47 at the end of fiscal 2025: current assets were 1.47 times current liabilities.